Fox Run Management, L.L.C. Alnylam Pharmaceuticals, Inc. Transaction History
Fox Run Management, L.L.C.
- $526 Million
- Q4 2024
A detailed history of Fox Run Management, L.L.C. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Fox Run Management, L.L.C. holds 2,809 shares of ALNY stock, worth $789,216. This represents 0.13% of its overall portfolio holdings.
Number of Shares
2,809
Previous 2,885
2.63%
Holding current value
$789,216
Previous $793,000
16.77%
% of portfolio
0.13%
Previous 0.18%
Shares
13 transactions
Others Institutions Holding ALNY
# of Institutions
671Shares Held
108MCall Options Held
839KPut Options Held
771K-
Capital World Investors Los Angeles, CA16.6MShares$4.66 Billion0.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.7MShares$3.58 Billion0.05% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.68 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA6.97MShares$1.96 Billion0.35% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.38MShares$1.23 Billion0.64% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $34.6B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...